Bottom line. The CMS Transforming Episode Accountability Model, or TEAM, creates a real 2026 demand signal for startups that can help hospitals manage surgical episodes, but it does not create automatic product-market fit. Physician investors should verify that a company serves actual TEAM participants, affects cost or quality inside a covered 30-day episode, can work from claims and clinical data quickly enough to change care, and prices its product below the value it credibly creates. The investable advantage is measured workflow impact, not a generic claim to enable value-based care.[1]

Key takeaways

  • TEAM is active from January 1, 2026, through December 31, 2030, and applies to selected hospitals across five surgical episode categories.
  • The hospital is the accountable participant. A startup must identify the economic buyer, operational owner, physician stakeholders, and post-acute partners around that participant.
  • Mandatory participation expands the addressable problem, but customer urgency varies by episode volume, financial-risk track, baseline performance, existing capabilities, and competing priorities.
  • The strongest vendor evidence connects a defined intervention to spending, utilization, quality, or patient-reported outcomes using a credible counterfactual and fully loaded implementation cost.
  • Monthly CMS data can support performance management, but claims lag, exclusions, risk adjustment, and attribution limit what a dashboard alone can prove.
  • Valuation should reward repeatable hospital deployment and verified episode economics while discounting policy concentration, long sales cycles, services intensity, and weak outcome attribution.

What TEAM changes for healthcare startup diligence

TEAM is a mandatory five-year CMS Innovation Center model. Selected acute care hospitals coordinate care for people with Original Medicare undergoing lower extremity joint replacement, surgical hip and femur fracture treatment, spinal fusion, coronary artery bypass graft, or major bowel procedures. An episode begins with the inpatient stay or hospital outpatient procedure and ends 30 days after the patient leaves the hospital. CMS listed 721 participants on its model page as of August 2, 2026.[1]

Hospitals continue to bill Medicare fee for service. CMS gives participants prospective target prices, compares actual included Parts A and B spending with those targets, and applies quality performance in reconciliation. A hospital may receive a payment when spending is below target or owe CMS when spending is above target, subject to model rules and its participation track.[1][4] The FY 2026 final rule refined target-price construction, broadened the three-day skilled nursing facility waiver, and incorporated outpatient patient-reported outcome performance without adding a separate reporting burden.[2]

The model creates an accountable customer, not a software budget

The hospital is the TEAM participant even though spending and recovery extend across surgeons, primary care, skilled nursing facilities, home health agencies, therapists, and other clinicians. This makes the participant a natural economic focal point, but purchasing authority can still sit in finance, population health, a service line, digital operations, information technology, quality, or a clinically integrated network. A startup that cannot name the budget owner and operational champion has identified a policy tailwind, not a customer.

CMS requires hospitals in selected Core-Based Statistical Areas to participate and periodically updates the hospital list for openings, closures, mergers, and other status changes. Hospitals may also have different safety-net, rural, or other classifications over time.[3] Investors should build the serviceable market from current Certification Numbers, episode volume, specialty mix, track eligibility, and real procurement access rather than multiplying a national hospital count by an assumed contract value.

Follow the economics from target price to workflow

A TEAM-related product matters only if it influences an economic or quality lever that the participant can capture. The January 2026 CMS target-price fact sheet describes regional and hospital-specific preliminary target prices. Hospital-specific calculations account for a benchmark price, prospective trend, normalization, risk adjustment, and a CMS discount. The stated discount is 1.5% for coronary bypass and major bowel episodes and 2% for joint replacement, hip and femur fracture treatment, and spinal fusion.[5] A vendor should be able to show where its value sits within that construction and subsequent reconciliation.

Separate addressable spend from avoidable spend

A large episode cost does not mean a large software opportunity. Some spending reflects the anchor procedure, patient complexity, appropriate post-acute care, or services outside the vendor's control. Ask management to quantify the portion affected by its intervention, the time needed to change behavior, and the share of improvement the hospital can retain after the CMS discount, quality adjustment, collaborator payments, and internal operating cost. This prevents total episode spending from being presented as vendor-addressable revenue.

Risk track changes urgency and willingness to pay

TEAM uses three participation tracks. All hospitals could use the no-downside Track 1 in performance year 1, while higher-risk Track 3 was also available. In later years, Track 1 and intermediate Track 2 are limited to eligible hospital types, and many participants move toward Track 3 by rule or default. CMS describes higher reward and downside exposure in Track 3.[3][8] This glide path can expand demand, but the timing is hospital-specific. A credible forecast links sales conversion and renewal to the customer's selected track, historical episode performance, and executive risk appetite.

Map each startup category to a provable TEAM value lever

Startup category Value evidence to request Common diligence trap
Episode analytics Reconciliation-aligned episode logic, service-setting spend, exclusions, target-price views, action logs, and forecast accuracy. A polished dashboard restates delayed claims without changing a decision or measuring realized value.
Care navigation and monitoring Enrollment, contactability, escalation response, avoidable acute use, readmissions, recovery milestones, and subgroup completion. Engagement metrics are treated as savings even when selection bias and clinical escalation costs are ignored.
Post-acute network management Discharge destination, length of stay, home health and skilled nursing use, quality, leakage, patient choice, and total spend. Lower facility use is assumed to be better without testing access, safety, caregiver burden, or appropriate utilization.
Patient education and recovery Comprehension, patient-reported outcomes, follow-up completion, complications, calls, emergency use, and workflow adoption. Content delivery is confused with understanding, behavior change, or a reimbursable quality improvement.

The model's quality design reinforces the need for specificity. CMS uses measures hospitals already report through other programs. The published measure set includes readmission, patient safety, joint-replacement patient-reported outcomes, and later outpatient recovery-information measures, with performance periods and applicability varying by year and episode type.[7] A vendor does not create value merely by displaying a measure. It must affect the underlying clinical process, data completeness, or decision early enough to change performance.

The physician investor's eight-part TEAM diligence framework

1. Verify customer and episode scope

Match every contracted and pipeline hospital to the current CMS participant list and Certification Number. Estimate annual volume by covered episode category, inpatient versus outpatient setting, baseline exclusions, and the product's actual use window. Confirm whether a multisite health-system agreement covers participant hospitals, nonparticipant affiliates, or both. Revenue attributed to TEAM should not include sites or procedures that cannot generate a TEAM episode.

2. Rebuild the customer value equation

For a representative hospital, start with eligible episodes, target-price and spending information, quality adjustment, track limits, and internal cost. Add the vendor's implementation, interface, clinical labor, outreach, training, and support expense. Then estimate a plausible change in the narrow driver the product affects. Show upside, base, and downside cases, including a case where the hospital improves but the product's contribution cannot be isolated.

3. Test the causal evidence, not just the outcome trend

Pre-post improvement can reflect case mix, surgeon behavior, coding, seasonal volume, network changes, regression to the mean, or another initiative. Review cohort definitions, comparison selection, timing, missing data, concurrent interventions, confidence intervals, and pre-specified outcomes. Physician advisors should assess whether avoided use was clinically appropriate and whether results generalize across the five very different procedure groups.

4. Trace data latency to an operational decision

CMS gives authorized participant data custodians access to baseline and monthly raw episode and claims files plus summary reports. The files include episode, setting, diagnosis, procedure, date, and amount information, but monthly claims remain retrospective.[6] Ask which decisions can be made from those files, which require near-real-time admission, discharge, transfer, EHR, patient, or partner data, and how the company reconciles preliminary operational views with final claims.

5. Inspect clinical workflow and safety

Observe how surgeons, nurses, navigators, therapists, primary care teams, and post-acute partners use the product. Review eligibility errors, escalation protocols, response times, language access, accessibility, caregiver roles, after-hours coverage, and handoffs. A workflow that reduces utilization by creating missed care, delayed evaluation, or unmanageable work is not a durable source of value. Confirm that clinicians can override recommendations and that overrides produce learning rather than silent workarounds.

6. Review contracting and beneficiary protections

Identify the contracting entity, data rights, implementation obligations, performance definition, fee at risk, termination rights, audit support, and allocation of savings claims. If the startup or its partners act as TEAM collaborators, obtain qualified review of the arrangement and its operational requirements. Patient choice and access remain important even when the model encourages coordinated post-acute pathways. Do not value a network strategy that depends on steering patients without appropriate protections or usable alternatives.

7. Underwrite integration and service intensity

Separate software gross margin from clinical services, implementation, interface maintenance, analytics support, and customer-specific reporting. Examine time to launch, data normalization, EHR dependency, security review, hospital change management, and support tickets by site. A company can show attractive contracted annual recurring revenue while consuming scarce implementation teams and cash for months before the first managed episode.

8. Price policy and concentration risk

TEAM lasts through 2030 under its current design, and CMS can refine operational details through rulemaking and guidance.[1] Model revenue by participant, health system, procedure category, product use case, and policy dependency. Stress-test a delayed reconciliation, narrower waiver, changed quality measure, hospital merger, track change, or customer bringing the function in house. A product that also solves a clinical and financial problem outside TEAM deserves more durable value than one built around a single report format.

Where current CMS operations create opportunity and constraint

The CMS data environment gives startups a common analytic substrate, but access and timeliness matter. Performance-year raw claims and episode summaries have been released monthly through the TEAM Custom Export Tool, while target-price information arrives on a different schedule.[6] Vendors should demonstrate versioned ingestion, episode reconstruction, late-claim handling, exclusion logic, and reconciliation to CMS reports. Investors should discount black-box projections that cannot explain a variance at the beneficiary, service-setting, or episode level.

CMS also implemented a TEAM telehealth waiver in 2026.[9] That can support remote follow-up models, but a waiver is not a standalone business model. Diligence still needs to address eligible services, clinician workflow, patient access, state and federal requirements, coverage outside the model, technology failure, and whether remote encounters change an outcome that matters to the participant.

Red flags that should change valuation or deal structure

  • Management multiplies all U.S. hospitals or all surgical spending by an assumed fee instead of using current TEAM participants and eligible episode volume.
  • The product tracks engagement or utilization but cannot tie results to target-price economics, quality, or a specific hospital decision.
  • Outcome claims rely on a small pre-post cohort with no credible comparison, no confidence intervals, or unexplained exclusions.
  • Claims data arrive after the decision window, while the company lacks a reliable source of timely clinical or workflow data.
  • Savings estimates exclude implementation labor, clinical escalation, interfaces, partner fees, or customer success cost.
  • A shared-savings or collaborator arrangement is central to revenue, but responsibility, patient protections, and qualified compliance review are unclear.
  • The pipeline is concentrated in health systems that already have internal episode analytics or navigation capabilities.
  • The company markets TEAM readiness across all five procedures but has evidence from only one comparatively standardized pathway.

A 100-day board plan after investment

In the first thirty days, verify participant customers, Certification Numbers, episode volumes, track assumptions, data rights, and the value equation for the three largest accounts. By day sixty, reproduce one CMS-aligned episode analysis, audit one clinical workflow from discharge through day 30, and agree on a customer-specific outcome and counterfactual. By day one hundred, publish an evidence scorecard, close critical integration and contracting gaps, validate fully loaded deployment margin, and give the board a concentration view by participant, procedure, policy dependency, and implementation team.

Frequently asked questions

What is the CMS TEAM model in plain English?

TEAM is a mandatory CMS Innovation Center model for selected acute care hospitals. It holds participating hospitals accountable for Medicare spending and quality across five types of surgical episodes, from the hospital procedure through 30 days after discharge, while ordinary fee-for-service billing continues.

Does mandatory TEAM participation guarantee customers for a startup?

No. It creates a defined problem and identifiable participant market, not a purchasing mandate. A startup still must prove that its product changes an actionable cost or quality driver, fits hospital operations, and produces savings or risk reduction that exceed its total implementation cost.

Which healthcare startups are most exposed to TEAM?

The most directly exposed categories include episode analytics, care navigation, post-discharge monitoring, patient education, rehabilitation support, post-acute network management, and specialty workflow tools. Exposure depends on actual hospital customers, covered procedures, integration, and the product's role during the 30-day episode.

What is the best proof-of-value metric for a TEAM vendor?

There is no universal metric. The most credible proof ties a specific intervention to an episode-level outcome the hospital can act on, such as standardized post-discharge spending, readmissions, emergency use, discharge destination, recovery information, or avoidable utilization, with a defensible comparison and implementation costs included.

How should investors value TEAM-related revenue?

Risk-adjust revenue by verified participant customers, eligible episode volume, track and financial exposure, budget ownership, contract durability, implementation capacity, and measured contribution. Do not apply a broad value-based-care premium to a pipeline that lacks hospital-level economics and attributable outcomes.

Conclusion

TEAM turns episode accountability into a current operating fact for hundreds of hospitals, creating focused opportunities for companies that improve surgical recovery, coordination, and spending. The opportunity is narrower and more testable than the phrase value-based care suggests. Physician investors should connect each product to an enrolled hospital, covered episode, timely decision, measurable outcome, defensible comparison, and capturable economic benefit. Credit repeatable evidence and workflow adoption; reserve for data lag, service burden, contract complexity, policy concentration, and attribution uncertainty. The best TEAM investment is a durable care capability that happens to benefit from the model, not a model narrative searching for a product.

References

  1. Centers for Medicare & Medicaid Services. TEAM (Transforming Episode Accountability Model), updated July 6, 2026. Accessed August 2, 2026. https://www.cms.gov/priorities/innovation/innovation-models/team-model
  2. Centers for Medicare & Medicaid Services. FY 2026 Hospital IPPS and LTCH PPS Final Rule Fact Sheet: Changes to the Transforming Episode Accountability Model. Accessed August 2, 2026. https://www.cms.gov/newsroom/fact-sheets/fy-2026-hospital-inpatient-prospective-payment-system-ipps-long-term-care-hospital-prospective-0
  3. CMS Innovation Center. Transforming Episode Accountability Model Frequently Asked Questions, updated 2026. Accessed August 2, 2026. https://www.cms.gov/priorities/innovation/files/team-technical-faqs.pdf
  4. CMS Innovation Center. Transforming Episode Accountability Model Overview Fact Sheet. Accessed August 2, 2026. https://www.cms.gov/files/document/team-model-fs.pdf
  5. CMS Innovation Center. Transforming Episode Accountability Model Preliminary Target Price Fact Sheet, updated January 2026. Accessed August 2, 2026. https://www.cms.gov/priorities/innovation/files/team-prelim-target-fs.pdf
  6. CMS Innovation Center. Transforming Episode Accountability Model Custom Export Tool Participant User Guide, Version 6.0, 2026. Accessed August 2, 2026. https://www.cms.gov/files/document/team-cet-portal-user-guide.pdf
  7. CMS Innovation Center. Quality Measures in the Transforming Episode Accountability Model. Accessed August 2, 2026. https://www.cms.gov/files/document/team-model-intro-qual-meas.pdf
  8. CMS Innovation Center. Participation Tracks in the Transforming Episode Accountability Model. Accessed August 2, 2026. https://www.cms.gov/files/document/team-participation-tracks-fact-sheet.pdf
  9. Centers for Medicare & Medicaid Services. Transmittal R13778DEMO: Transforming Episode Accountability Model Telehealth Waiver Implementation, May 19, 2026. Accessed August 2, 2026. https://www.cms.gov/medicare/regulations-guidance/transmittals/2026-transmittals/r13778demo

Editorial disclaimer: This article is for educational purposes only and does not constitute medical, legal, tax, accounting, reimbursement, regulatory, or investment advice. CMS models, payment rules, quality measures, waivers, and company circumstances are fact-specific and can change. Readers should consult qualified professionals and verify current primary sources before acting.